Scientific article

Maladies osseuses : ce qui a changé en 2023

Published inRevue médicale suisse, vol. 20, no. 859, p. 255-258
First online date2024-01-31

The sequential effects of romosozumab and denosumab in osteoporosis are shown in real-life, while the mechanisms of post-denosumab rebound are reviewed extensively. A network meta-analysis confirms the superiority of anabolics vs anti-resorptives on fracture reduction, while the latter shown a reduction of mortality in a large population-based study. Fracture risk prediction by FRAXPlus is improved. New meta-analyses confirm the benefits of Vitamin D on fractures and falls. Finally, multiples trials with new molecules for the treatment of rare bone diseases, including osteogenesis imperfecta, fibrous dysplasia and hypoparathyroidism, shown promising results.

Citation (ISO format)
FERRARI, Serge Livio et al. Maladies osseuses : ce qui a changé en 2023. In: Revue médicale suisse, 2024, vol. 20, n° 859, p. 255–258. doi: 10.53738/REVMED.2024.20.859.255
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 08/01/2025
ISSN of the journal1660-9379

Technical informations

Creation02/05/2024 10:21:44 AM
First validation04/15/2024 7:58:21 AM
Update time04/15/2024 7:58:21 AM
Status update04/15/2024 7:58:21 AM
Last indexation04/15/2024 7:58:42 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack